Application of polyether compounds K-41B and K-41Bm derived from K-41A in preparation of anti-HIV drugs
The invention discloses an application of polyether compounds K-41B and K-41Bm derived from K-41A in preparation of an anti-HIV (Human Immunodeficiency Virus) drug. According to the invention, three cytovirus infection models of TZM-bl-HIV-1IIIB, MT-2-HIV-1IIIB and peripheral blood mononuclear cells (PBMCs)-HIV-1BaL are adopted to verify the anti-HIV activity of the polyether compounds. The anti-HIV-1 activity research of polyether compounds K-41B and K-41Bm derived from marine natural products K-41A is carried out in HIV-1 virus strains with different tropism by adopting three cell infection systems for the first time, and the potential anti-HIV action mechanisms of the polyether compounds K-41B and K-41Bm are disclosed by combining multiple experiments, so that the application has original innovativeness, and is a novel application of the polyether compounds K-41B and K-41Bm in HIV-1 virus strains with different tropism. Moreover, the invention finds that K-41B and K-41Bm are possibly potential anti-HIV-1 multi-target inhibitors, effectively inhibit the replication of HIV-1IIIB and HIV-1BaL viruses, have broad-spectrum anti-HIV-1 activity, can be used for preventing or treating HIV infection, and become potential anti-HIV drugs..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 23. Juni Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
YE LI [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-06-23, Last update posted on www.tib.eu: 2023-11-21, Last updated: 2023-11-24 |
|---|
| Patentnummer: |
CN116270590 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA018101127 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA018101127 | ||
| 003 | DE-627 | ||
| 005 | 20231124095411.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231006s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA018101127 | ||
| 035 | |a (EPA)CN116270590 | ||
| 035 | |a (EPA)86802583 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a YE LI |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Application of polyether compounds K-41B and K-41Bm derived from K-41A in preparation of anti-HIV drugs |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-06-23, Last update posted on www.tib.eu: 2023-11-21, Last updated: 2023-11-24 | ||
| 520 | |a The invention discloses an application of polyether compounds K-41B and K-41Bm derived from K-41A in preparation of an anti-HIV (Human Immunodeficiency Virus) drug. According to the invention, three cytovirus infection models of TZM-bl-HIV-1IIIB, MT-2-HIV-1IIIB and peripheral blood mononuclear cells (PBMCs)-HIV-1BaL are adopted to verify the anti-HIV activity of the polyether compounds. The anti-HIV-1 activity research of polyether compounds K-41B and K-41Bm derived from marine natural products K-41A is carried out in HIV-1 virus strains with different tropism by adopting three cell infection systems for the first time, and the potential anti-HIV action mechanisms of the polyether compounds K-41B and K-41Bm are disclosed by combining multiple experiments, so that the application has original innovativeness, and is a novel application of the polyether compounds K-41B and K-41Bm in HIV-1 virus strains with different tropism. Moreover, the invention finds that K-41B and K-41Bm are possibly potential anti-HIV-1 multi-target inhibitors, effectively inhibit the replication of HIV-1IIIB and HIV-1BaL viruses, have broad-spectrum anti-HIV-1 activity, can be used for preventing or treating HIV infection, and become potential anti-HIV drugs. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a LIANG HAO |4 aut | |
| 700 | 0 | |a ZHOU BO |4 aut | |
| 700 | 0 | |a CHEN HUI |4 aut | |
| 700 | 0 | |a LIU JIE |4 aut | |
| 700 | 0 | |a LIU XIN |4 aut | |
| 700 | 0 | |a WEI QIUYU |4 aut | |
| 700 | 0 | |a JIANG JUNJUN |4 aut | |
| 700 | 0 | |a LIANG BINGYU |4 aut | |
| 700 | 0 | |a HUANG JIEGANG |4 aut | |
| 700 | 0 | |a PAN PEIJIANG |4 aut | |
| 700 | 0 | |a CHU JIEMEI |4 aut | |
| 700 | 0 | |a QIN FENGXIANG |4 aut | |
| 700 | 0 | |a ZHAN YUJIE |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 23. Juni |
| 773 | 1 | 8 | |g year:2023 |g day:23 |g month:06 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/86802583/publication/CN116270590A1?q=CN116270590 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 23 |c 06 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 23 |c 06 | ||